APG Research, LLC | Orlando, FL
Status and phase
Conditions
Treatments
About
ML-004-003 is a multi-center, open-label extension study that will enroll approximately 120 adolescent and adult subjects with ASD that have completed study ML-004-002. The primary objective of the study will be to evaluate the safety of ML-004 in subjects with ASD.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
120 participants in 1 patient group
Loading...
Central trial contact
Kelly Amaguin
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal